RxDoctor Payments Data

Dana Baumgartner

Family · Spokane, WANPI 1356732960

Payments from drug & device makers

$822in general payments, 2019–2025

Across 29 payments — averaging $28.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$274
  • Radius Health, Inc.$114
  • Ascendis Pharma Endocrinology Inc$78
  • Medtronic$56
  • Lilly USA, LLC$53
  • Corcept Therapeutics$44
  • plus $203 from 8 others

What the payments were for

  • Food & beverage$80798%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$822 in reported general payments places this provider in the 75th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$18,832
Medicare patients
127
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$54,282
MounjaroTirzepatide34$45,511
OzempicSemaglutide32$43,534
Tresiba Flextouch U-200Insulin Degludec16$19,834
Tresiba Flextouch U-100Insulin Degludec32$19,670
TrulicityDulaglutide13$18,189
Humalog Kwikpen U-100Insulin Lispro23$6,702
HumalogInsulin Lispro24$4,528
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,583
SynthroidLevothyroxine Sodium20$2,099
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic15$1,455
Droplet Pen NeedlePen Needle, Diabetic12$1,324
Levothyroxine Sodium102$1,200
Metformin Hcl37$695
Metformin Hcl ErMetformin Hcl32$406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$53$68,22871 claims
Novo NordiskOzempic$274$43,53432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,706 family providers in Washington.

Other family in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →